nSMOL Monoclonal Antibody Bioanalysis

 
 
 

Publication lists from SHIMADZU

Selective detection of complementarity‐determining regions of monoclonal antibody by limiting protease access to the substrate: nano‐surface and molecular‐orientation limited proteolysis.
Iwamoto N*, Shimada T**, Umino Y, Aoki C, Aoki Y, Sato T, Hamada A, Nakagama H.
Analyst. 2014. 139(3):576-80. DOI: 10.1039/c3an02104a.
https://pubs.rsc.org/en/content/articlelanding/2014/AN/C3AN02104A#!divAbstract

 

The development of the validated LCMS bioanalysis of trastuzumab in human plasma using a selective detection method for complementarity‐determining regions of monoclonal antibodies: nano‐surface and molecular‐orientation limited (nSMOL) proteolysis.
Iwamoto N*, Yamane N, Umino Y, Hamada A. and Shimada T**.
Analytical Methods. 2015. 21:9177‐83. DOI: 10.1039/C5AY01588J
https://pubs.rsc.org/en/content/articlelanding/2015/ay/c5ay01588j#!divAbstract

 

Fully validated LCMS bioanalysis of Bevacizumab in human plasma using nano‐surface and molecular-orientation limited (nSMOL) proteolysis.
Iwamoto N*, Umino Y, Aoki C, Yamane N, Hamada A, Shimada T**.
Drug Metabolism and Pharmacokinetics. 2016. 31(1):46‐50. DOI: 10.1016/j.dmpk.2015.11.004.
https://www.sciencedirect.com/science/article/pii/S1347436715000695?via%3Dihub

 

Application of nano‐surface and molecular‐orientation limited proteolysis to LC‐MS bioanalysis of cetuximab.
Iwamoto N*, Takanashi M, Umino Y, Aoki C, Hamada A, Shimada T**.
Bioanalysis. 2016. 8(10):1009‐20. DOI: 10.4155/bio‐2016‐0018.
https://www.future-science.com/doi/abs/10.4155/bio-2016-0018?rfr_dat=cr_pub%3Dpubmed&url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&journalCode=bio

 

Validated LC/MS Bioanalysis of Rituximab CDR Peptides Using Nano‐Surface and Molecular‐Orientation Limited (nSMOL) Proteolysis.
Iwamoto N*, Takanashi M, Hamada A, Shimada T**.
Biological and Pharmaceutical Bulletin. 2016. 39(7):1187‐94. DOI: 10.1248/bpb.b16‐00230.
https://www.jstage.jst.go.jp/article/bpb/39/7/39_b16-00230/_article

 

Validated LC-MS/MS analysis of immune checkpoint inhibitor Nivolumab in human plasma using a Fab peptide-selective quantitation method: nano-surface and molecular-orientation limited (nSMOL) proteolysis.
Iwamoto N*, Shimada T*, Terakado H, Hamada A**.
Journal of Chromatography B Analytical Technologies in the Biomedical and Life Sciences. 2016.
1023‐1024:9‐16. DOI: 10.1016/j.jchromb.2016.04.038.
https://www.sciencedirect.com/science/article/pii/S157002321630277X?via%3Dihub

 

Multiplex LCMS Bioanalysis of Brentuximab Vedotin, Rituximab, and Cetuximab towards Therapeutic Drug Monitoring Application by Combined Calibration Curve Using Fab‐Selective Limited Proteolysis nSMOL
Iwamoto N*, Takanashi M, Hamada A, Shimada T**.
Clinical Pharmacology and Biopharmaceutics. 2016. 5:164. DOI: 10.4172/2167‐065X.1000164
https://www.omicsonline.org/open-access/multiplex-lcms-bioanalysis-of-brentuximab-vedotin-rituximab-and-cetuximab-towards-therapeutic-drug-monitoring-application-by-combi-2167-065X-1000164.php?aid=79879

 

LC‐MS bioanalysis of Trastuzumab and released emtansine using nano‐surface and molecular‐orientation limited (nSMOL) proteolysis and liquid‐liquid partition in plasma of Trastuzumab emtansine‐treated breast cancer patients.
Iwamoto N*, Shimomura A, Tamura K, Hamada A, Shimada T**.
Journal of Pharmaceutical and Biomedical Analysis. 2017. 145:33‐39. DOI: 10.1016/j.jpba.2017.06.032.
https://www.sciencedirect.com/science/article/pii/S0731708517311822?via%3Dihub

 

Antibody drug quantitation in coexistence with anti‐drug antibodies on nSMOL bioanalysis.
Iwamoto N*, Hamada A, Shimada T**.
Analytical Biochemistry. 2018. 540‐541:30‐37. DOI: 10.1016/j.ab.2017.11.002.
https://www.sciencedirect.com/science/article/pii/S0003269717304311?via%3Dihub

 

Recent advances in mass spectrometry‐based approaches for proteomics and biologics: Great contribution for developing therapeutic antibodies.
Iwamoto N*, Shimada T**.
Pharmacology & Therapeutics. 2018. 185:147‐154. DOI:
10.1016/j.pharmthera.2017.12.007. Review.
https://www.sciencedirect.com/science/article/pii/S0163725817303042?via%3Dihub

 

Verification between Original and Biosimilar Therapeutic Antibody Infliximab Using nSMOL Coupled LC‐MS Bioanalysis in Human Serum.
Iwamoto N*, Yokoyama K, Takanashi M, Yonezawa A, Matsubara K, Shimada T**.
Current Pharmaceutical Biotechnology. 2018. 19(6):495‐505. DOI:
0.2174/1389201019666180703093517.
http://www.eurekaselect.com/163418/article

Application of nSMOL coupled with LC-MS bioanalysis for monitoring the Fc-fusion biopharmaceuticals Etanercept and Abatacept in human serum.
Iwamoto N*, Yokoyama K, Takanashi M, Yonezawa A, Matsubara K, Shimada T**.
Pharmacology Research & Perspectives. 2018. 6(4):e00422. DOI: 10.1002/prp2.422.
https://bpspubs.onlinelibrary.wiley.com/doi/full/10.1002/prp2.422

 
 

Regulated LC‐MS/MS bioanalysis technology for therapeutic antibodies and Fc‐fusion proteins using structure-indicated approach.
Iwamoto N*, Shimada T**.
Drug Metabolism and Pharmacokinetics. 2019. 34(1):19‐24. DOI: 10.1016/j.dmpk.2018.10.002. Review.
https://www.sciencedirect.com/science/article/pii/S1347436718301393?via%3Dihub

 
 

Acceleration of nano‐surface and molecular‐orientation limited (nSMOL) proteolysis with acidified reduction pretreatment for quantification of Tocilizumab.
Iwamoto N*, Yonezawa A, Matsubara K, Shimada T**.
Journal of Pharmaceutical and Biomedical Analysis. 2019. 164:467‐474. DOI: 10.1016/j.jpba.2018.11.019.
https://www.sciencedirect.com/science/article/abs/pii/S073170851832209X?via%3Dihub

 

Multiplexed monitoring of therapeutic antibodies for inflammatory diseases using Fab‐selective proteolysis nSMOL coupled with LC‐MS.
(Infliximab, Adalimumab, Ustekinumab, Golimumab, Eculizumab, Etanercept, Abatacept, Tocilizumab, and Mepolizumab)
Iwamoto N*, Takanashi M, Yokoyama K, Yonezawa A, Denda M, Hashimoto M, Tanaka M, Ito H, Matsuura M, Yamamoto S, Honzawa Y, Matsubara K, Shimada T**.
Journal of Immunological Methods. 2019. 472:44‐54. DOI: 10.1016/j.jim.2019.06.014.
https://www.sciencedirect.com/science/article/pii/S0022175919301413?via%3Dihub

 
 

Comparison of bevacizumab quantification results in plasma of non‐small cell lung cancer patients using bioanalytical techniques between LC‐MS/MS, ELISA, and microfluidic‐based immunoassay.
Iwamoto N*, Takanashi M, Shimada T**, Sasaki J, Hamada A**.
The AAPS Journal of the American Association of Pharmaceutical Scientists. 2019. 21:101. DOI: 10.1208/s12248‐019‐0369‐z
https://link.springer.com/article/10.1208%2Fs12248-019-0369-z

 
 
 

Structure‐indicated LC‐MS/MS bioanalysis of therapeutic antibodies.
Iwamoto N*, Shimada T**.
Methods in Molecular Biology. In press.

 

Publication from our customers:

A novel LC-MS/MS approach to the pharmacokinetic study of free and bound aflibercept simultaneously. Kong L, Liu F, Huo L, Sha C, Liu W, Yu F.
Analytical and Bioanalytical Chemistry. 2020 412(4):1003-1010. DOI: 10.1007/s00216-019-02316-w
https://link.springer.com/article/10.1007%2Fs00216-019-02316-w

 
 

Human endotrophin as a driver of malignant tumor growth.
Bu D, Crewe C, Kusminski CM, Gordillo R, Ghaben AL, Kim M, Park J, Deng H, Xiong W, Liu XZ, Lønning PE, Halberg N, Rios A, Chang Y, Gonzalez A, Zhang N, An Z, Scherer PE.
JCI Insight. 2019 Mar 21;5. pii: 125094. DOI: 10.1172/jci.insight.125094.
https://insight.jci.org/articles/view/125094

 
 

Plasma infliximab monitoring contributes to optimize Takayasu arteritis treatment: a case report. Masui S, Yonezawa A, Izawa K, Hayakari M, Asakura K, Taniguchi R, Isa M, Shibata H, Yasumi T, Nishikomori R, Takita J, Matsubara K.
Journal of Pharmaceutical Health Care and Sciences. 2019 5:9. DOI: 10.1186/s40780-019-0136-4.
https://jphcs.biomedcentral.com/articles/10.1186/s40780-019-0136-4

 
 

What sample preparation should be chosen for targeted MS monoclonal antibody quantification in human serum?
Vialaret J, Broutin S, Pugnier C, Santelé S, Jaffuel A, Barnes A, Tiers L, Pelletier L, Lehmann S, Paci A, Hirtz C. Bioanalysis. 2018 May 1;10(10):723-735. DOI: 10.4155/bio-2018-0027
https://www.future-science.com/doi/abs/10.4155/bio-2018-0027?rfr_dat=cr_pub%3Dpubmed&url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&journalCode=bio

 
 
 

Current Mass Spectrometric Tools for the Bioanalyses of Therapeutic Monoclonal Antibodies and Antibody-Drug Conjugates.
Todoroki K, Yamada T, Mizuno H, Toyo'oka T.
Analytical Sciences. 2018;34(4):397-406. DOI: 10.2116/analsci.17R003.
https://www.jstage.jst.go.jp/article/analsci/34/4/34_17R003/_article

 
 

The 8th Japan Bioanalysis Forum symposium. Matsumaru T.
Bioanalysis. 2017 Nov;9(22):1733-1737. DOI: 10.4155/bio-2017-0193.
https://www.future-science.com/doi/10.4155/bio-2017-0193?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dwww.ncbi.nlm.nih.gov

 
 

Development of an LC-MS/MS method with protein G purification strategy for quantifying bevacizumab in human plasma.
Chiu HH, Tsai IL, Lu YS, Lin CH, Kuo CH.
Analytical and Bioanalytical Chemistry. 2017 Nov;409(28):6583-6593. DOI: 10.1007/s00216-017-0607-0.
https://link.springer.com/article/10.1007%2Fs00216-017-0607-0

For Research Use Only. Not for use in diagnostic procedures.

This page may contain references to products that are not available in your country. Please contact us to check the availability of these products in your country.

Top of This Page